Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $796.08. Get Regeneron Pharmaceuticals alerts:View Our Latest Report on REGNRegeneron Pharmaceuticals Stock PerformanceNASDAQ:REGN traded down $1.77 during midday trading on Monday, reaching $760.86. Key Regeneron Pharmaceuticals NewsHere are the key news stories impacting Regeneron Pharmaceuticals this week:Regeneron Pharmaceuticals Company Profile(Get Free Report)Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. See AlsoReceive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.